专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08465917B2 Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells 有权
标题翻译：确定肝细胞癌亚型和检测肝癌干细胞的方法
公开(公告)号：US08465917B2
公开(公告)日：2013-06-18
申请号：US12663586
申请日：2008-06-09
申请人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
发明人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178 , G01N33/6893
摘要： The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.
摘要翻译：本发明提供了确定受试者中HCC亚型的方法，其包括a）从受试者获得样品，b）测定样品以检测1种或更多种生物标志物的表达，以及c）将生物标志物的表达与HCC相关联受试者的亚型。本发明还提供了检测样品中HCC干细胞的方法。另外，本发明提供用于治疗HCC受试者利用与HCC干细胞相关的生物标志物的方法和组合物。

2. 发明申请

US20100197770A1 Methods for Determining Heptocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells 有权
标题翻译：确定肝细胞癌亚型和检测肝癌干细胞的方法
公开(公告)号：US20100197770A1
公开(公告)日：2010-08-05
申请号：US12663586
申请日：2008-06-09
申请人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
发明人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
IPC分类号： A61K31/7088 , C12Q1/68 , C40B30/04 , C12Q1/02 , G01N33/559
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178 , G01N33/6893
摘要： The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.
摘要翻译：本发明提供了确定受试者中HCC亚型的方法，其包括a）从受试者获得样品，b）测定样品以检测1种或更多种生物标志物的表达，以及c）将生物标志物的表达与HCC相关联受试者的亚型。本发明还提供了检测样品中HCC干细胞的方法。另外，本发明提供用于治疗HCC受试者利用与HCC干细胞相关的生物标志物的方法和组合物。

3. 发明授权

US09464324B2 Methods of determining the prognosis of an adenocarcinoma 有权
标题翻译：确定腺癌预后的方法
公开(公告)号：US09464324B2
公开(公告)日：2016-10-11
申请号：US12373191
申请日：2007-07-16
申请人： Curtis C. Harris , Masahiro Seike , Xin Wei Wang
发明人： Curtis C. Harris , Masahiro Seike , Xin Wei Wang
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.
摘要翻译：公开了用于确定受试者在器官如肺中具有腺癌的预后的方法。该方法可以包括定量表达多种目的细胞因子，如IL-1a，IL-1b，IL-2，IL-8，IL-10，IL-12，IL-15，IFN-γ和TNF- a在腺癌和器官中的非癌组织中。与对照组和非对照组相比，腺癌中IL-1a，IL-1b，IL-2，IL-8，IL-10，IL-12，IL-15，IFN-γ和TNF-α的表达改变，与对照相比，器官中的癌组织决定了对象的预后。还公开了用于确定治疗剂是否有效作为抗癌剂的方法。

4. 发明申请

US20120294870A1 COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS 失效
标题翻译：用于诊断和治疗肿瘤的组合物和方法
公开(公告)号：US20120294870A1
公开(公告)日：2012-11-22
申请号：US13549633
申请日：2012-07-16
申请人： Vivian Takafuji , Xin Wei Wang , Edward J. Unsworth , Paul K. Goldsmith
发明人： Vivian Takafuji , Xin Wei Wang , Edward J. Unsworth , Paul K. Goldsmith
IPC分类号： C07K16/24 , A61K39/395 , C40B30/00 , G01N33/566 , C12Q1/68 , C12N5/18 , G01N33/577 , G01N21/76 , C12N15/13 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , A61P35/00 , C12N5/09
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译：基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。还提供包括这些试剂的治疗组合物。还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。还提供了特异性结合OPN-5kD的抗体。

5. 发明授权

US5985829A Screening assays for compounds that cause apoptosis and related compounds 失效
公开(公告)号：US5985829A
公开(公告)日：1999-11-16
申请号：US675631
申请日：1996-07-01
申请人： Curtis C. Harris , Xin Wei Wang , Jan H. J. Hoeijmakers
发明人： Curtis C. Harris , Xin Wei Wang , Jan H. J. Hoeijmakers
IPC分类号： A61K38/00 , A61K38/17 , C07K14/47 , A61K38/08 , A61K38/16 , C07K7/06 , C07K14/00
CPC分类号： A61K38/1709 , C07K14/4746 , C07K2319/00
摘要： This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.

6. 发明授权

US07803380B2 Compositions and methods for diagnosis and treatment of tumors 有权
标题翻译：用于诊断和治疗肿瘤的组合物和方法
公开(公告)号：US07803380B2
公开(公告)日：2010-09-28
申请号：US12340211
申请日：2008-12-19
申请人： Vivian Takafuji , Xin Wei Wang
发明人： Vivian Takafuji , Xin Wei Wang
IPC分类号： A61K39/38 , A61K38/00
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译：基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。还提供包括这些试剂的治疗组合物。还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。还提供了特异性结合OPN-5kD的抗体。

7. 发明申请

US20090258789A1 METHODS OF DETERMINING THE PROGNOSIS OF AN ADENOCARCINOMA 有权
标题翻译：确定腺苷酸的预处理方法
公开(公告)号：US20090258789A1
公开(公告)日：2009-10-15
申请号：US12373191
申请日：2007-07-16
申请人： Curtis C. Harris , Masahiro Seike , Xin Wei Wang
发明人： Curtis C. Harris , Masahiro Seike , Xin Wei Wang
IPC分类号： C12Q1/68 , C40B40/06 , C40B30/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.
摘要翻译：公开了用于确定受试者在器官如肺中具有腺癌的预后的方法。该方法可以包括定量表达多种目的细胞因子，如IL-1a，IL-1b，IL-2，IL-8，IL-10，IL-12，IL-15，IFN-γ和TNF- a在腺癌和器官中的非癌组织中。与对照组和非对照组相比，腺癌中IL-1a，IL-1b，IL-2，IL-8，IL-10，IL-12，IL-15，IFN-γ和TNF-α的表达改变，与对照相比，器官中的癌组织决定了对象的预后。还公开了用于确定治疗剂是否有效作为抗癌剂的方法。

8. 发明授权

US07005419B1 Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity 失效
标题翻译：用于鉴定GADD45多肽活性抑制剂的方法和这种活性的抑制剂
公开(公告)号：US07005419B1
公开(公告)日：2006-02-28
申请号：US10600158
申请日：2003-06-20
申请人： Xin Wei Wang , Curtis C. Harris , Albert J. Fornace, Jr. , Jill D. Coursen , Qimin Zhan
发明人： Xin Wei Wang , Curtis C. Harris , Albert J. Fornace, Jr. , Jill D. Coursen , Qimin Zhan
IPC分类号： A61K38/00
CPC分类号： G01N33/5008 , C07K14/47 , G01N33/5011 , G01N33/68 , G01N33/6842 , G01N2500/00
摘要： The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.
摘要翻译：本发明涉及用于测定GADD45多肽活性调节剂的新方法。本发明还提供了通过施用GADD45多肽活性的新型抑制剂使增殖细胞对DNA碱损伤剂敏感的方法。本发明还提供了干扰Cdc2 /细胞周期蛋白B1复合物响应于GADD45在细胞周期的G2 / M阶段停止的能力的多肽，以及编码这种多肽的核酸。

9. 发明授权

US06613318B1 Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity 有权
标题翻译：用于鉴定GADD45多肽活性抑制剂的方法和这种活性的抑制剂
公开(公告)号：US06613318B1
公开(公告)日：2003-09-02
申请号：US09534811
申请日：2000-03-24
申请人： Xin Wei Wang , Curtis C. Harris , Albert J. Fornace, Jr. , Jill D. Coursen , Qimin Zhan
发明人： Xin Wei Wang , Curtis C. Harris , Albert J. Fornace, Jr. , Jill D. Coursen , Qimin Zhan
IPC分类号： A61K4500
CPC分类号： G01N33/5008 , C07K14/47 , G01N33/5011 , G01N33/68 , G01N33/6842 , G01N2500/00
摘要： The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.
摘要翻译：本发明涉及用于测定GADD45多肽活性调节剂的新方法。本发明还提供了通过施用GADD45多肽活性的新型抑制剂使增殖细胞对DNA碱损伤剂敏感的方法。本发明还提供了干扰Cdc2 /细胞周期蛋白B1复合物响应于GADD45在细胞周期的G2 / M阶段停止的能力的多肽，以及编码这种多肽的核酸。

10. 发明授权

US06602979B1 Screening assays for compounds that cause apoptosis 失效
标题翻译：导致凋亡的化合物的筛选试验
公开(公告)号：US06602979B1
公开(公告)日：2003-08-05
申请号：US08359316
申请日：1994-12-19
申请人： Curtis C. Harris , Xin Wei Wang , Jan H. J. Hoeijmakers
发明人： Curtis C. Harris , Xin Wei Wang , Jan H. J. Hoeijmakers
IPC分类号： C07K1400
CPC分类号： A61K38/1709 , C07K14/4746 , C07K2319/00
摘要： This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.
摘要翻译：本发明涉及筛选能够诱导某些肿瘤细胞凋亡的化合物的方法。本发明还涉及通过这些方法鉴定的化合物。此外，本发明涉及用于这些方法中有用的皮肤色素调色剂和化合物的体外诊断方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式